Patisiran - Pharmacology, Uses, Warnings, and Precautions

Overview:

The United States (US) Food and Drug Administration (FDA) validated Patisiran’s curative aspects in hereditary transthyretin-mediated amyloidosis (hATTR), which is a progressive ailment that is prompted by genetic errors or discrepancies. In August 2018, the FDA sanctioned the curative use of Patisiran for designated cases. Patisiran has also been advocated for hATTR patients flagging restrictive cardiomyopathy. However, the FDA does not warrant this usage. Apart from the FDA, the European Medicine Agency (EMA) also licensed Patisiran for hereditary transthyretin-mediated amyloidosis patients. This article delves into Patisiran’s pharmacological and therapeutic aspects.

Drug Group:

RNA (ribonucleic acid) interference therapeutics is the specific drug class to which Patisiran is conferred. Being an exotic and novel drug class, RNAi (RNA interference) therapeutics are less known to the public. However, its ideation was a quantum leap for various genetic conditions.

Available Doses and Dosage Forms:

• Dosage Forms: Liquid form intended for delivery through drip (infusion).

• Available Doses: In the 10 milligrams (mg) concentration per five milliliters (mL).

For Patients:

What Is Hereditary Transthyretin-Mediated Amyloidosis?

Hereditary transthyretin-mediated amyloidosis (hATTR) is an unfamiliar and infrequent condition marked up by the atypical gathering of a proteinaceous material. Amyloid is the medical term that ascribes to the gathered deposits. As a genetically piloted condition, the TTR (transthyretin) gene’s anatomical disparities or deviations instigate hATTR development.

The TTR gene encodes the production signals for the transthyretin protein. This protein is obligatory for conveying thyroxine (thyroid hormone) and retinol (vitamin A). Four structural units of transthyretin protein molecules collaborate, giving rise to the functionally active form (tetramer). The TTR gene transfiguration disables the tetramer formation. As a result, instead of tetramer formation, deformed individual TTR protein molecules club over one another, forming amyloid deposits, which eventually result in hATTR.

These deposits then cling to various organs, including the brain, heart, spinal cord, kidney, and eyes, precipitating functional disparities. Clinical indications of hereditary transthyretin-mediated amyloidosis become more transparent in the early twenties. However, some may elicit manifestations even later. A major part of the patients detected with hATTR highlights a familial connection with the condition, which indicates that the genetic defect is being channeled through generations. However, there are instances of hATTR with no familial linkage.

How Does Patisiran Work?

Patisiran is an RNAi therapeutic medicine that works at the gene level. It is structured to interact with the altered TTR gene’s messenger RNA. Messenger RNA, otherwise regarded as mRNA, bears the data pertaining to the concerned protein. The interaction between mRNA and RNAi impedes the generation of structurally altered transthyretin protein molecules. Thus, Patisiran successfully masks the altered TTR gene’s expression. In this way, Patisiran could bring down the abnormal protein generation, which mediates the development of hereditary transthyretin-mediated amyloidosis.

What Is the Dosage of Patisiran?

• Patient With Body Weight Under 100 Kilograms: 0.3 milligrams of Patisiran per kilogram (kg) of body weight on a tri-weekly basis.

• Patients With Body Weight Over 100 Kilograms: 30 milligrams (mg) of Patisiran bi-weekly.

How Effective Is Patisiran?

Patisiran holds a remarkable efficacity profile concerning hereditary transthyretin-mediated amyloidosis. Patisiran gears down the advancement of hereditary transthyretin-mediated amyloidosis. It ameliorates neuronal impairments and even holds back further amyloid deposition. Patisiran heightens the patients’ life quality by alleviating the clinical manifestations of hereditary transthyretin-mediated amyloidosis, including numbness, weakness, compromised reflexes and thermal perception, and trouble walking accompanied by soreness.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Allergy History: Keep the medical professional posted on unexplainable sensitivity episodes confronted with Patisiran. Caution should be exercised in cases that had flagged suspicious allergic issues with any other drug formulation of the RNA interference therapeutic category.

• Medical History: Medical history clues to the patient's present medical status. Notify the physician regarding concomitant ailments, medical therapies, or surgical modalities undertaken.

• Drug History: Drug history refers to the descriptive documentation exposing all the medicines that one takes. Drug history holds the prospects for piloting the drug choice.

• Pregnancy: Doctors should be notified of patients' lactating and pregnancy status. Both cases mandate thorough assessment before Patisiran therapy initiation.

How Is Patisiran Administered?

• Only trained medical professionals, doctors, or nurses dispense Patisiran.

• Wait for Patisiran delivery until the injection solution attains room temperature.

• Extract the specific volume of filtered Patisiran injection solution into a germ-free syringe.

• Patisiran solution is then thinned out by releasing it into the 200 milliliters of Sodium chloride solution.

• Dilution is achieved by ejecting the Patisiran solution into the Sodium chloride infusion bag (0.9 percent concentration).

• The resulting Patisiran solution is dispensed into the vein through an infusion line.

• During infusion initiation (15 minutes), the infusion rate is regulated at one milliliter per minute, which is then increased to three milliliters per minute for Patisiran infusion.

What Are the Side Effects of Patisiran?

Adverse effects of Patisiran include the following:

• Respiratory tract infections.

• Indigestion.

• Breath shortness.

• Muscle spasm.

• Joint soreness and stiffness.

• Infusion site soreness and redness.

• Dizziness.

• Blood pressure fluctuations.

• Chest heaviness.

• Heart racing.

• Cough and chills.

• Facial puffiness.

Dietary Considerations:

Patisiran does not mandate alterations in dietary choices unless advocated by the doctor. Adherence to a healthy diet is instituted in all other cases.

Missed Dose:

It is better advised not to miss or forgo any dose, as it could hamper the potency of the Patisiran therapy.

• Missed Dose Recalled in Under Three Days: Dispense Patisiran and continue with the standard course.

• Missed Dose Noticed Three Days Later: Dispense Patisiran and modify the dosing course, considering the dispensing day as the drug delivery date for the upcoming dose. The upcoming dose can be advocated after a three-week break from the dispensing day.

Overdose:

Close surveillance of the patient’s vital parameters is advocated for instances of Patisiran overdose. Initiate pertinent steps to counter-tackle and mitigate the overdose issues.

Storage:

• Optimum Storage Temperature: 36 to 46 degrees Fahrenheit (two to eight degrees Celsius).

• Optimum Storage Condition: Refrigeration, but no freezing of Patisiran infusion solution.

• Room Temperature Storage: Safer for 14 days.

• Storage Post Patisiran Dilution: Patisiran formulation is preservative-free, limiting storage hours post Patisiran dilution. Sixteen hours is the permissible storage duration post-dilution, under 30 degrees Celsius.

For Doctors:

Indications:

• Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (adult patients).

Dose:

An individual’s body weight is interpreted as the decisive criterion in Patisiran’s dose calculation. 0.3 milligrams (mg) per kilogram (kg) of body weight is the customarily prescribed tri-weekly dosage for all patients whose body weight is gauged to be below 100 kilograms. For the remaining category of patients (with a body weight surpassing 100 kilograms), a uniform triweekly dosage of 30 milligrams of Patisiran is advocated.

Mandatory Premedication:

Patisiran therapy mandates a specific premedication regimen to mark down the side effects. One hour ahead of the Patisiran infusion, the premedication regimen needs to be delivered. The premedication regimen is inclusive of the following drugs:

• Acetaminophen (500 mg - oral route).

• Diphenhydramine (50 mg - intravenous route).

• Dexamethasone (10 mg - intravenous route).

• Ranitidine (50 mg - intravenous route).

Suppose the patient cannot tolerate or take the intravenous route. In that case, all the drugs quoted in the premedication regimen can be orally ingested by tablet form drugs of the corresponding infusion dose. Similarly, if issues are encountered with corticosteroid premedication, incremental down-regulation of the corticosteroid dose can be advocated. However, depreciating the corticosteroid dose beyond five milligrams may hamper the premedication coverage and, hence, not be proposed.

What Are the Pharmacological Aspects of Patisiran?

• Mechanism of Action: The Patisiran is formulated in siRNA (small interfering RNA) structure. This structural design renders Patisiran the potential for dampening the genomic expression of the chosen gene. Here, in Patisiran, the siRNA is structured counter to mute the transfigured TTR gene’s protein expression, and it is guided through a sequence of processes. siRNA, a tiny RNA strip, elicits its action by integrating with RISC (RNA-induced silencing complex). siRNA hinders atypical TTR mRNA translation and eventually attenuates amyloid deposit gathering. In this way, the altered TTR gene is governed and guided by Patisiran, thus masking hereditary transthyretin-mediated amyloidosis.

• Pharmacodynamics: Around 80 percent TTR concentration scaling down is reported with a single Patisiran dose. The scaling down hits 88 percent with the Patisiran course for 1.5 years. Furthermore, Patisiran therapy also punctuates vitamin A and retinol-binding proteins’ serum equilibrium.

• Pharmacokinetics: Being an infusion medicine, Patisiran is dispensed into the blood, and in no time does Patisiran mark its existence in the serum. Twenty-four weeks of Patisiran therapy is entailed for the siRNA molecules to secure a steady state. In the bloodstream, Patisiran gets disseminated, particularly to the hepatic tissues. Patisiran’s dissemination is chiefly through lipid complex interaction, while an insignificant fraction gets assistance from plasma protein. Nucleases eat up the Patisiran’s siRNA structure and shatter the RNA strip into nucleotides, thus constituting the Patisiran’s elimination channel. Unprocessed Patisiran molecules that have sneaked away from nuclease activity get expelled through urine.

Toxicity:

Patisiran toxicity is precipitated by Patisiran overdosage. Supportive manoeuvers counter-tack the Patisiran overdosage. Since Patisiran delivery is advocated only in hospital settings, its scope for overdose is minimal. Nevertheless, being in a hospital, there is a provision for swift interventional response to Patisiran toxicity instances. Patisiran overdosing may call forth visual disparities. Employ surveillance of the patient’s vital parameters and body functioning in Patisiran overdose instances. Patisiran’s other toxicity aspects, including mutagenicity, carcinogenicity, and tumorigenicity, were quite appreciative, given in vitro studies with no evident potentialities. Nonclinical studies also entitled Patisiran a clean chart concerning fertility impairment. However, Patisiran’s toxicity profile craves further scrutiny to establish indisputable and ultimate results, which need to be backed with scientific evidence.

Clinical Studies:

Placebo-controlled, randomized, multicentric, and double-blinded clinical studies have authenticated and evidenced Patisiran’s therapeutic capabilities, particularly efficacy. This study also substantiated the safety aspects concerning Patisiran therapy. An exaggerated dampening of polyneuropathy signs was identified and documented with the control group subjects who were trialed with Patisiran. The multicentric nature of the Patisiran clinical study exposed that the Patisiran holds equivalent effectivity in patients from diverse geographies, as symptomatic recovery elicited with Patisiran therapy was analogous in all the study centers. Neither the patient's location nor their age and sex do matter for Patisiran potency.

What Are the Contraindications of Patisiran?

Patisiran does not hold many contraindications, which heightens its applicability. Some of the Patisiran’s contraindications are as follows:

• Allergy to Patisiran.

• Intolerability to interference RNA therapeutics.

Warnings and Precautions:

• Depreciates Vitamin A Level: Patisiran dramatically reduces the Vitamin A proportion in the serum, necessitating supplementation during Patisiran therapy. Vitamin A supplements, as per the instructed dose, need to be adhered to. However, the dose should not exceed the advocated daily allowance.

• Vision Troubles: Throughout Patisiran therapy, the patient’s vision should be intermittently evaluated. Collapsed vitamin A level evoked by Patisiran may precipitate ocular issues like night blindness.

• Infusion-Related Reactions (IRRs): Patients undergoing Patisiran therapy are exposed to IRR development. The infusion-related reactions can be in the form of belly pain, back pain, headache, flushing, and dyspnea. A premedication course inclusive of antihistamines, Acetaminophen, and corticosteroids is warranted to check infusion-related reactions with Patisiran therapy. Nevertheless, at times, Patisiran triggers IRRs despite premedication, during which the infusion needs to be halted. Augmented doses of premedications are advocated in such patients upon subsequent Patisiran therapy.

What Are the Drug Interactions of Patisiran?

Being an iRNA product, Patisiran neither interferes nor augments cytochrome enzymes. There is no data available that flags any drug association with Patisiran. However, to be on the safer side, consider the potentialities when Patisiran is clubbed with other medicines as it is not explored much concerning the drug interaction aspects.

Specific Considerations:

• Patisiran During Pregnancy: Expectant women are not routinely advocated for Patisiran therapy. However, there is only sparse scientific data about the dangers Patisiran therapy can evoke in pregnant ladies. Patisiran therapy can precipitate serum vitamin A depreciation. If vitamin A insufficiency happens in a pregnant woman, it can potentially reflect complications and threats for the maternal as well as fetal body, giving rise to developmental issues.

• Patisiran During Lactation: Lactating women should desist Patisiran therapy unless their concerned doctor institutes it. Not much data is accessible on how Patisiran behaves in a lactating mother’s body. Patisiran’s influence over breast milk production and its channeling into the fetus needs to be inquired into to declare Patisiran’s use in this specific population.

• Patisiran in Pediatric Patients: Patisiran’s application is bound to adults. It is neither validated nor advocated for the younger population (pediatric patients).

• Patisiran in Geriatric Patients: Patisiran’s therapeutic potentialities were reportedly analogous to those of the adult groups in patients over 65.